Arbeitsgruppe Neurodegenerative Erkrankungen
1. Mitarbeiter
Leiter: Univ.-Prof. Dr. Werner Poewe / Univ.-Prof. Dr. Gregor K. Wenning
Mitarbeiter: OA Dr. Sylvia Bösch, OA Dr. Christian Brenneis, OA Dr. Wolfgang Löscher, OA Dr. Jörg Müller, Dr. Anja Diem (Drittmittel), Dr. Tanja Entner (Drittmittel), Dr. Martin Furtner, Dr. Felix Geser, Dr. Klaus Seppi, Dr. Martin Sojer, Dr. Christoph Scherfler, Dr. Michaela Stampfer, Dr. Nadia Stefanova (Drittmittel), Dr. Elisabeth Wolf, Dr. Karoline Kunz (Drittmittel), Dr. Katherina Mair (Drittmittel), Dr. Martin Köllensperger (Drittmittel)
2. Drittmittel
a) Kompetitive Drittmittel
2000 EU Projekt QLRT-2000-00661 "European MSA Study Group" (Internationales Verbundprojekt mit 24 europäischen Partnerzentren unter Führung der Innsbrucker Universitätsklinik für Neurologie)
2001 FWF Projekt P14633-PHA "Neuroprotektion im Rattenmodell der MSA"
2001 EU Projekt "EuroPa: European Cooperative Network for Research, Diagnosis, and Therapy of Parkinson`s disease"
2001 ÖNB Jubiläumsfond-Projekt Nr. 8199 ("Österr. Demenzdatenbank")
b) Preise
Dr. M. Schocke/ Dr. K. Seppi - Posterpreis: Annual Meeting of the American Academy of Neurology; Philadelphia, PA; May 5-12, 2001. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD, M.F.H. Schocke, K. Seppi, R. Esterhammer, C. Kremser, W. Jaschke;W. Poewe; G. K. Wenning.
Dr. Zoe Puschban Birkmayerpreis: Neurorestauration und -regeneration mittels embryonaler Transplantation in einem Tiermodell der MSA. ÖPG-Meeting Innsbruck März 2001
Dr. L. Kirchmair/ Dr. T. Entner - Posterpreis: 19 th Annual Meeting of the European Society of Tregional Anesthesia (ESRA), September 2000, Rom, Ultrasound (US) guided psoas compartment block (PCB): anatomical fundamentals L. Kirchmair, T. Entner, R. Burger, J. Wissel, B. Moriggl, H. Maurer, G. Mitterschiffthaler
c) Industrie gesponserte Drittmittel ("unrestricted research grants") und klinische Prüfungen
Pergolid-Studie B4G-EW-LBAG, Sponsor: ELI LILLY CO, Dauer 1995 - 2000
Riluzol bei M. Parkinson RP54274X-320, Sponsor: AVENTIS, Dauer März 1999 - 2002
Ropinirol-Studie -Studie 101468/125 und 170 (Folgestudie), Sponsor: SMITHKLINE BEECHAM, Dauer März 1998 bis Okt. 2000 (125); Okt. 2000 bis 2004 (170)
Sumanirol-Studie M/2760/0010 und 666E-CNS-0075-0019 (Folgestudie), Sponsor: PHARMACIA, Dauer März 2000 - 2004
Rondo-Studie TV 1203/116, 118 (Folgestudie 1) und 118A (Folgestudie 2), Sponsor. TEVA, Dauer Aug. 2000 - Jänner 2003
Largo-Studie TV 1012/122, 123 (Folgestudie 1) und 124 (Folgestudie 2), Sponsor. TEVA Dauer Aug. 2000 - 2005
Riluzole bei M. Huntington RIL.DE1.201, Sponsor. AVENTIS Dauer Nov. 2001 - 2004
SP513-Studie und SP513-Extension (Folgestudie 1), Sponsor. SCHWARZ BIOSCIENCES, Dauer März 2002 - Sep. 2003
Amantadin-Studie Klinische Eigenstudie, Dauer Nov. 2001 - 2003
Serono-Studie, Sponsor: SERONO, Dauer Dez. 2001 - 2003
Express-Studie CENA713B2311 Sponsor: NOVARTIS, Dauer Jänner 2003 - 2003
Advans-Studie NS2330, Sponsor: BOEHRINGER INGELHEIM, Dauer April 2003 - Ende 2003
Sumanirol DA2APD-0075-031, Sponsor: PHARMACIA, Dauer April 2003 - Ende 2003
Dystonie: Allergan grant (1997-2002)
Botulinum Toxin Typ A bei zerebralparetischen Kindern mit Adduktorenspastik (Dys 7 HE50), Sponsor: IPSEN
Dysport - Studie Adduktorenspastik (Dysport 042) Sponsor: IPSEN
Dysport ® (Botulinum Toxin A) mit 500 versus 1000 U bei der Behandlung der schmerzhaften Spastik der oberen Extremitäten nach Schlaganfall. (Dysport 016) Sponsor: IPSEN Beginn 2000
Olanzapin - Studie Sponsor: ELI LILLY CO - Beginn 2000
NT201 (hochreines Botulinum Neurotoxin A) im Vergleich zu Botox (reines Botulinum Neurotoxin A-Komplex) bei zervikaler Dystonie klinisches Forschungsprojekt, Beginn 2001, MERZ & CO KG
AN072-402CD, NeuroBloc® (Botulinum Toxin Typ B) im Vergleich mit Botox (Botulinum Toxin Typ A) bei cervikaler Dystonie, Sponsor: ELAN Beginn 2002
AN072-401CD/EU Immunogenität von NeuroBloc® (Myobloc; Botulinum Toxin Typ B) bei cervikaler Dystonie Sponsor: ELAN Beginn 2002
Demenz: Forschungszuschüsse für Demenzdatenbank / Fa. Novartis, Fa. Pfizer
ALS-Projekt: Apoptosis signals in sporadic amyotrophic lateral sclerosis: an immunocytochemical study
Reisezuschuß des Ö.A.D-Büro für wissenschaftlich-technische Zusammenarbeit (Ö-Israel), Projekt Nr. III.7)
3. Publikationen
a) Orginalarbeiten
Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK (2000). Autoradiographic study of striatal dopamine reuptake sites and dopamine D1 and D2 receptors in a 6.hydroxydopamine and quinolinic acid double lesion rat model of striatonigral dgeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Neurosci 2000;95:377-88
Wenning GK, Jellinger KJ, Quinn NP, Poewe WH (2000). An early report of striatonigral degeneration. Mov Disord 2000;15:159-62
Wenning GK, Tison F, Scherfler C, Puschban Z, Waldner R, Granata R, Ghorayeb I, Poewe W (2000). Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. Cell Transplant 2000;9:279-88
Donnemiller E, Brenneis C, Wissel J, Poewe W, Riccabona G, Wenning GK (2000). Impaired dopaminergic neurotransmission in patients with traumatic brain injury using 123I-ß-CIT and 123I-IBZM. Eur J Nucl Med 2000;27:1410-4
Wenning GK, Ben Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP (2000). What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson`s disease? J Neurol Neurosurg Psychiatry 2000;68:434-40
Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I (2000). Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology, 2000;55:888-891
Puschban Z, Waldner R, Seppi K, Stefanova N, Humpel C, Scherfler C, Levivier M, Poewe W, Wenning GK (2000). Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). Exp Neurol 2000;164:166-75
Scherfler C, Puschban Z, Ghorayeb I, Goebel GP, Weiler B, Tison F, Poewe W, Wenning GK (2000). Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration. Neurosci 2000;99:43-54
Ghorayeb I, Fernagut PO, Aubert I, Bezard E, Wenning GK, Tison F (2000). Toward a primate model of L-Dopa unresponsive parkinsonism mimicking striatonigral degeneration. Mov Disord 2000;15:531-6
Luginger E, Wenning GK, Bösch S, Poewe W (2000). Beneficial effects of amantadine on L-Dopa induced dyskinesias in Parkinson`s disease. Mov Disord 2000;15:873-8
Schocke MF, Waldner R, Puschban Z, Kolbitsch C, Seppi K, Scherfler C, Kremser C, Zschiegner F, Felber S, Poewe W, Wenning GK (2000). In vivo magnetic resonance imaging of embryonic neural grafts in a rat model of striatonigral degeneration (multiple system atrophy). Neuroimage 2000;12:209-18
Kofler M, Muller J, Reggiani L, Wenning GK (2000). Somatosensory evoked potentials in progressive supranuclear palsy. J Neurol Sci 2000;179:85-91
Waldner R, Puschban Z, Scherfler C, Seppi K, Jellinger K, Poewe W, Wenning GK (2000). No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic rat model of advanced striatonigral degeneration (multiple system atrophy). Neurosci 2001;102:581-592
Kofler M, Müller J, Wenning GK, Reggiani L, Hollosi P, Bösch S, Ransmayr G, Valls-Solé J, Poewe W (2001). The auditory startle reaction in parkinsonian disorders. Mov Disord 2001;16:62-71
Müller J, Wenning GK, Verny M, McKee A, Ray Chauduri K; Jellinger K, Poewe W, Litvan I (2001). Progression of dysarthria and dysphagia in postmortem confirmed parkinsonian disorders. Arch Neurol 2001;58:259-264
Ghorayeb I, Puschban Z, Fernagut PO, Scherfler C, Rouland R, Wenning GK, Tison F (2001). Simultaneous intra-striatal 6-hydoxydopamine and quinolinic acid injection: a model of early stage striatonigral degeneration (multiple system atrophy). Exp Neurol 2001;167:133-147
Marras C, Lang AE, Ang LC, Zijlmans JCM, Wenning GK (2001). Clinical Grand Rounds. A 69 year-old man with gait disturbance and parkinsonism. Mov Disord 2001;16:548-61
Müller J, Wenning GK, Bösch S, Wissel J, Poewe W (2001). Intrafamilial heterogeneity of facial hyperkinesias: chance association of tics, cranial dystonia, and Huntington's disease? Mov Disord 2001;16:370-2
Müller J, Wissel J, Masuhr F, Ebersbach G, Wenning GK, Poewe W (2001). Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol 2001;248:478-482
Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M (2001). Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 2001;65:432-438
Högl B, Seppi K, Brandauer E, Wenning GK, Poewe W (2001). Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): a placebo-controlled polysomnographic case report. Mov Disord 2001;16:1177-9
Seppi K, Bodner T, Brandauer E, Mueller J, Benke T, Weirich H, Poewe W, Wenning GK (2001). Riluzole in Huntington`s disease: an open label study with one year follow-up. J Neurol 2001;248:866-9
Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, Poewe W, Wenning GK (2001). Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's Disease. Eur J Ncl Med 2001;28(10):1523-8
Wenning GK, Seppi K (2001). Diagnosis and therapy of multiple system atrophy. Schweiz Rundsch Med Prax 2001, 90(23):1035-40
Wenning GK, Braune S (2001). Multiple system atrophy: pathophysiology and management. CNS Drugs 2001, 15(11):839-52
Müller J, Wenning GK, Wissel J, Baldauf A, Seppi K, Brenneis C, Poewe W (2002). Riluzole therapy in cervical dystonia. Mov Disord 2002;17:198-200
Bösch SM, Wenning GK, Ransmayr G, Maier H, Jellinger K, Poewe W (2002). Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002, 72(3):300-303
Schocke MFH, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, Wenning GK (2002). Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002, 58:575-580
Wenning GK, Seppi K, Tison F, Jellinger K (2002). A novel grading scale for striatonigral degeneration (multiple system atrophy). J Neural Transm 2002, 109:307-320
Jellinger K, Seppi K, Wenning GK, Poewe W (2002). Impact of coexistent Alzheimer pathology on the natural history of Parkinson`s disease. J Neural Transm 2002, 109:329-339
Stefanova N, Emgard M, Klimaschewsky L, Wenning GK, Reindl M (2002). Ultrastructure of alpha-synuclein positive glial aggregations in vitro. Neurosci Lett 2002, 327(1)37-40
Ebersbach G, Sojer M, Müller J, Ransmayr G, Wenning G, Poewe W (2002). Gleichgewichtsstörungen bei idiopathischer Parkinson-Erkrankung: der Einfluss cerebrovaskulärer Komorbidität. Nervenarzt 2002;73 (2);162-165.
Scherfler C, Donnemiller E, Schocke M, Dierkes K, Decristoforo C, Oberladstätter M, Kolbitsch C, Zschiegner F, Riccabona G, Poewe W, Wenning G (2002). Evaluation of striatal dopamine transporter function in rats by in-vivo ß-123I-CIT pinhole SPECT . NeuroImage 17, 182-141, 2002
Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, Wenning GK, for the MSA-Aquitaine Network and for the European MSA Study Group (2002). Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III) and disability assessment compared to Parkinson's disease. Mov Disord 2002, Jul;17((4):701-9
Müller J, Kiechl S, Wenning GK, Seppi K, Willeit J, Gasperi A, Wissel J, Gasser T, Poewe W (2002). The prevalence of primary dystonia in the general community. Neurology 2002, 59:941-943
Müller J, Seppi K, Stefanova N, Poewe W, Litvan I, Wenning GK (2002). Freezing of gait in post-mortem-confirmed atypical parkinsonism. Mov Disord 2002, 17(5):1041-5
Tison F, Yekhlet F, Chrysostome V, Sourgen C, Wenning GK, Poewe W (for the MSA-Aquitaine Network and for the European MSA Study Group) (2002). Symptom profile and severity of cerebellar ataxia in multiple system atrophy: a clinical study using the Internatinal Cooperative Ataxia Scale (ICARS). Mov Disord 2002, 17(4):701-9
Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W of the Austrian Botulinum Toxin and Dystonia Study Group (2002). The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002, 249/7):842-6
Fernagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F (2002). Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57B1/6 mice: behavioural and hiostopathological characterization. Neurosci 2002, 114(4):1005
Bauer I, Gencik M, Laccone F, Peters H, Weber BHF, Holinski-Feder E, Weirich-Schwaiger H, Wenning GK, Morris-Rosendahl DJ, Rolfs A, Gencik S, Epplen JT, Holmes SE, Margolis RL, Ross CA, Riess O (2002). Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotype. Ann Neurol 2002, 51(5):662
Adorjan P, Schwabe L, Wenning G, Obermayer K (2002). Rapid adaptation to internal states as a coding strategy in visual cortex ? Neuroreport 2002, 13(3):337-42.
Osaki Y, Wenning GK, Daniel SE, Hughes A, Lees AJ, Mathias CJ, Quinn N (2002). Do published criteria improve clinical diagnostic accuracy in multiple system atrophy ? Neurology 2002, 59(10):1486-1491
Müller J, Wenning GK, Wissel J, Seppi K, Poewe W (2002). Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 2002, 249(3):300-4,
Högl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, Ulmer H, Wenning G, Poewe W (2002). Modafanil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25(8):905-9.
Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Tison F (2002). Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic MPTP+ 3-nitropropionic acid primate model of striatonigral degeneration in monkeys. Neurosci Lett 2002;335:34-8.
Tison F, Yekhlef F, Balestre E, Chrysostome V, Quinn N, Wenning GK, Poewe W (2002). Application of the International Cooperative Ataxia Scale rating in multiple system atrophy. Mov Disord 2002;17:1248-54.
Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, Wenning G, Poewe W (2003). Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003;18:319-23.
Seppi K, Schocke M, Esterhammer R, Kremser C, Brenneis C, Müller J, Bösch S, Jaschke W, Poewe W, Wenning GK (2003). Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-7.
b) Übersichtsartikel/Buchbeiträge
Poewe W, Wenning GK (2000). Apomorphine - an underutilized therapy of Parkinson`s disease. Mov Disord 2000, 15:789-94
Stefanova N, Seppi K, Scherfler C, Puschban Z, Wenning GK (2000). Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment. J Neural Transm 2000;60:335-343
Wenning GK, Puschban Z, Seppi K, Scherfler C (2000). Aktuelle Aspekte zur Diagnostik und Therapie der Multisystematrophie. Schweiz Archiv Neurol Psychiatr 2000;151:150-158
Wenning GK, Poewe W, Seppi K (2000). Morbus Parkinson - Klinik und Therapie. Ärztemagazin 2000, 39:16-18
Ransmayr G, Wenning GK, Seppi K, Jellinger K, Poewe W (2000). Demenz mit Lewy-Körperchen. Nervenarzt 2000, 71:929-935.
Poewe W, Seppi K, Wenning GK (2000). Morbus Parkinson und andere extrapyramidale Bewegungsstörungen bei geriatrischen Patienten. Klinik - Sonderausgabe Geriatrie, 10. Jg. 1/2000, 22
Wenning GK, Seppi K (2001). Diagnostik und Therapie der Multisystematrophie. Praxis 2001;90:1035-1040
Wenning GK, Seppi K, Scherfler C, Stefanova N, Puschban Z (2001). Multiple system atrophy. Semin Neurol 2001, 21(1):33-40
Wenning GK, Diem A, Michlmayr S, Schocke M, Seppi K, Poewe W (2001). Atypische Parkinson-Syndrome. Aktuelle Neurologie 2001, 28:S3, 242-245
Wenning GK, Michlmayr S, Braune S, Brücke T, Fogel W, Gerster P, Schulz JB, Volkmann J (2001). Empfehlungen zur Differentialdiagnose von Parkinson-Syndromen. Aktuelle Neurologie 2001, 28:S3, 256-260
Wenning GK (2001). Atypische Parkinson-Syndrome. DNP 2001, 11:26-33
Wenning G (2001). Pergolid. Der Mediziner 2001, 5:13
Luginger E, Wenning GK, Bösch S, Poewe W (2001). Amantadin bessert L-Dopa induzierte Dyskinesien bei Morbus Parkinson. Psycho 2001, 27(7):389-393.
Poewe W, Wenning GK (2002). The differential diagnosis of Parkinson's disease. Eur J Neurol 2002; 9(3):23-30
Puschban Z, Stefanova N, Wenning GK (2002). Neural Transplantation in MSA rat models. Prog Neurobiol, 2002
F. Tison, F. Yekhlef, E. Balestre, V. Chrysostome, N. Quinn, G. K. Wenning, W. Poewe (2002). Evaluation of cerebellar ataxia in multiple system atrophy using the International Cooperative Ataxia Rating Scale (ICARS), Mov Disord, 2002
Wenning GK, Geser F (2002). Multiple system atrophy. Revue Neurologique, 2002
Wenning GK, Poewe W (2002). The "risus sardonicus" of multiple system atrophy (MSA). J Neurol Neurosurg Psychiat 2002
Poewe W, Wenning GK (2000). Sicher therapieren mit Parkinsonmitteln. PMG Verlag, Kössen, 2000
C. Scherfler, K. Seppi, Z. Puschban, B. Weiler, H. Granbichler, W. Poewe and G. K. Wenning (2001). Nigral Degeneration in animal models of multiple system atrophy. In: A. Storch, M. A. Collins (Hrsg). Neurotoxic Factors in Parkinson's Disease and Related Disorders Kluwer Academic/Plenum Publisher, 2001, New York, 65-68
Poewe W, Wenning GK (2001).The natural history of Parkinson`s disease. In: Wells Medical Ltd., 2001
Poewe W, Wenning GK (2002). Atypical parkinsonism. In: T Brandt, Caplan L, Dichgans J, Diener HC, Kennard C (Hrsg). Treatment of neurological disorders, Academic Press, 2002
Poewe W, Wenning GK (2002). Levodopa in Parkinson`s disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds). Parkinson`s disease and movement disorders. Williams and Wilkins, 2002, Baltimore
Quinn NP, Wenning GK (2002). Multiple system atrophy. In: Jankovic J, Tolosa E (eds). Parkinson`s disease and movement disorders. Williams and Wilkins, 2002, Baltimore
Poewe W, Wenning GK (2002). Morbus Parkinson. Arcis, 2002, München
Poewe W, Wenning GK (2002). Morbus Parkinson, Teil 2 "Spätphase". In: Conrad B, Ceballos-Baumann A (eds). Bewegungsstörungen. Thieme, 2002
Quinn Np, Wenning GK (2002). Multiple system atrophy. Butterworth Heinemann, 2002, London
Wenning GK, Seppi K, Jellinger K (2002). Diagnostic Accuracy in Lewy Body Dementia. Neurodegenerative Disorders associated to alpha-synuclein pathology. Tolosa E (ed.), 2002
Poewe W, Wenning GK (2002). Atypische Parkinson-Syndrome. Therapie und Verlauf neurologischer Erkrankungen, 4. Auflage, Kapitel H.2. Brandt T, Dichgans J, Diener C (ed.), 2002
Wenning GK, Geser F. Multiple system atrophy. In: Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics. Eds. Beal, Lang, Ludolph, Professional Publishers Group, Cambridge University Press, 2003, im Druck
c) Letters
Wenning GK, Poewe W (2000). Journal Club 1038 (Barone et al. Pergolidmonotherapie im Frühstadium des Morbus Parkinson: eine randomisierte, kontrollierte Studie). InFo Neurologie & Psychiatrie 2000;2/2:1
Kofler M, Wenning GK, Poewe W, Jellinger K, Maier H (2000). Cortical and brainstem hyperexcitability in a pathologically confirmed case of multiple system atrophy. Mov Disord 2000;15:362-363
Jellinger KA, Wenning GK (2000). An early description of striatonigral dgeneration. J Neurol 2000;247:309-12
Seppi K, Puschban Z, Stefanova N, Scherfler C, Mueller J, Poewe W, Wenning GK (2001). Overstimulation of the alpha 1B-adrenergic receptor causes a seizure plus syndrome. Nat Med 2001;7:132
Wenning GK, Diem A (2001). Editorial: Is peripheral neuropathy a feature of multiple system atrophy? Clin Aut Res 2001, 11(2):63
Wenning GK, Poewe W (2001). Journal Club 2193 (Freed et al. Transplantation embryonaler dopaminerger Neurone bei fortgeschrittener Parkinson-Krankheit). InFo Neurologie & Psychiatrie 2001;3:1, 6
Abbruzzese G, Agid Y, Albanese A, Claue A ….., Wenning GK et al. An open letter to the Committee on the Nobel Prize in Medicine. Parkinsonism and Related Disorders 2001, 7:149-155
Wenning GK (2001). Pergolid. Der Mediziner 2001, 13
Wenning GK (2002). M. Parkinson - Klinik und Therapie. Ärztemagazin 2002, Sonderheft, 14.12.2002, 14-16.
Jellinger KA, Seppi K, Wenning GK (2003). Accuracy of diagnosis in dementia with Lewy bodies. Arch Neurol 2003, 60:452-3.
4. Dissertationen und Diplomarbeiten
Baldauf Angelika 2000 Untersuchung zur Veränderung klinischer Befunde und ganganalytischer Parameter durch wiederholte Botulinum Toxin Typ A-Injektionen bei Kindern mit Zerebralparese und dynamischem Spitzfuß
Lutz Sigrid 2000 Nosographie der Demenz mit Lewy-Koerperchen im Vergleich zum Idiopathischen Parkinson Syndrom mit Demenz
Dierkes Katja 2001 In vivo imaging of dopamine transporter function in rat striatum using pinhole SPECT and 123I-beta-CIT: coregistered with small animal MRI
Koehler Almut 2001 L-Dopa monotherapy in patients with Parkinson's disease
Kricek Jan 2001 MRI-based volumetry in multiple system atrophy (MSA) and Parkinson's disease
Warscher Markus 2001 MR-based volumetry in differential diagnosis of Parkinson´s disease and progressive supranuclear palsy (PSP)
Frauscher Birgit 2001 Inzidenz des Restless Legs Syndroms nach Spinalanaesthesien
Marcher Barbara 2001 Freezingepisoden an der oberen Extremitaet bei Patienten mit Morbus Parkinson - Erfassung von Schreibblockaden mittels einer Video-EMG-Polygraphie und Schreibanalyse
Meier Hannes Joachim 2002 The role of routine magnetic resonance imaging in the differential diagnosis of multiple system atrophy and Parkinson´s disease
Apochal Alexandra 2002 Der Einfluss nicht-steroidaler Antirheumatika auf die Zytokin induzierte Amyloid-beta Produktion bei Mb.Alzheimer
Burtscher Doris 2002 Development and Validation of a Teaching Tape for the Motor Section of the Unified Multiple System Atrophy Rating Scale (UMSARS).
Pernter Helga 2002 Feinmotorikstörungen bei Patienten mit idiopatschem Parkinsonssyndrom- Untersuchung mittels 3D-Ultraschall-System
Anja Diem 2003 Mortality in patients with Parkinson's disease: A Tyrolean cohort study
Laura Mantoan 2003 Effects of caspase inhibition in the double lesion SND rat model
Monika Mitschnigg 2003 Effects of minocycline in a MSA double lesion rat model
5. Organisation wissenschaftlicher Kongresse
06/2000 Organisation der 2. EMSA-SG Konferenz, Barcelona
09/2000 International Organising Committee, Alpine Basal Ganglia Club, Lubljana
03/2001 Head of Local Organising Committee, Joint Meeting of Austrian Parkinson Society and Alpine Basal Ganglia Club, Innsbruck
03/2001 Fortbildungsseminar "Atypische Parkinsonsyndrome", 2. Deutscher Parkinson-Kongreß
05/2001 Co-Organisation der 3. EMSA-SG Konferenz, London
02/2002 Alp`s Course of the Movement Disorders Society, Kitzbühel
05/2002 Organisation des Annual General Meeting, EMSA-SG, Innsbruck
02/2003 Organisation des Workshop Atypical parkinsonism: from protein dysfunction to therapeutic intervention - mit Unterstützung der MDS, Innsbruck